Implementation of the French Nationwide Cystic Fibrosis Newborn Screening Program

Journal of Pediatrics

Volumn 153, Issue 2, 2008, Pages

  Munck, Anne ^a,b   Dhondt, Jean Louis ^b,c   Sahler, Camille ^b   Roussey, Michel ^b,d  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b French Assoc for the Prevention and Screening of Children's Disabilities   (France)

^c UNIVERSITÉ CATHOLIQUE DE LILLE   (France)

^d RENNES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TRYPSINOGEN;

ARTICLE; CYSTIC FIBROSIS; FALSE POSITIVE RESULT; HEALTH PROGRAM; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; NEWBORN; NEWBORN SCREENING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SWEAT TEST;

EID: 47049095800     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2008.02.028     Document Type: Article

References (34)

1. Farriaux J.P., Dorche C., and Travert G. Cystic fibrosis: what is the incidence?. Arch Fr Pediatr 50 (1993) 540-541
2. Accurso F.J., Sontag M.K., and Wagener J.S. Complications associated with symptomatic diagnosis in infants with cystic fibrosis. J Pediatr 147 (2005) S37-S41
3. Campbell P.W., and White T.B. Newborn screening for cystic fibrosis: an opportunity to improve care and outcomes. J Pediatr 147 (2005) S2-S5
4. Farrell P.M., Kosorok M.R., Rock M.J., Laxova A., Zeng L., Lai H.C., et al. Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Pediatrics 107 (2001) 1-13
5. Siret D., Bretaudeau G., Branger B., Dabadie A., Dagorne M., David V., et al. Comparing the clinical evolution of cystic fibrosis screened neonatally to that of cystic fibrosis diagnosed from clinical symptoms: a 10-year retrospective study in a French region (Brittany). Pediatr Pulmonol 35 (2003) 342-349
6. Dankert-Roelse J.E., and Meerman G.J. Long-term prognosis of patients with cystic fibrosis in relation to early detection by neonatal screening and treatment in a cystic fibrosis centre. Thorax 50 (1995) 712-718
7. Sims E.J., McCormick J., Mehta G., and Mehta A. Neonatal screening for cystic fibrosis is beneficial even in the context of modern treatment. J Pediatr 147 (2005) S42-S46
8. Scotet V., de Braekeleer M., Roussey M., Rault G., Parent P., Dagorne M., et al. Neonatal screening for cystic fibrosis in Brittany, France: assessment of 10 years' experience and impact on prenatal diagnosis. Lancet 356 (2000) 789-794
9. Brouard J., Lecoq I., Viel J.F., Guillot M., Laurans M., Laroche D., et al. Evaluation of diagnosis and follow-up in screened children with cystic fibrosis in Normandy. Arch Pediatr 8 Suppl 3 (2001) 603-609
10. Audrezet M.P., Costes B., Ghanem N., Fanen P., Verlingue C., Morin J.F., et al. Screening for cystic fibrosis in dried blood spots of newborns. Mol Cell Probes 7 (1993) 497-502
11. Farriaux J.P., Vidailhet M., Briard M.L., Belot V., and Dhondt J.L. Neonatal screening for cystic fibrosis: France rises to the challenge. J Inherit Metab Dis 26 (2003) 729-744
12. Dhondt J.L. Implementation of informed consent for a cystic fibrosis newborn screening program in France: low refusal rates for optional testing. J Pediatr 147 (2005) S106-S108
13. Ferec C., Verlingue C., Parent P., Morin J.F., Codet J.P., Rault G., et al. Neonatal screening for cystic fibrosis: result of a pilot study using both immunoreactive trypsinogen and cystic fibrosis gene mutation analyses. Hum Genet 96 (1995) 542-548
14. Claustres M., Guittard C., Bozon D., Chevalier F., Verlingue C., Ferec C., et al. Spectrum of CFTR mutations in cystic fibrosis and in congenital absence of the vas deferens in France. Hum Mutat 16 (2000) 143-156
15. Gibson L.E., and Cooke R.E. A test of concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing policarpine by ioneophoresis. Pediatrics 23 (1959) 545-549
16. Collins C.E., McDonald-Wicks L., Rowe S., O'Loughlin E.V., and Henry R.L. Normal growth in cystic fibrosis associated with a specialised centre. Arch Dis Child 81 (1999) 241-246
17. Rosenstein B.J., and Cutting G.R. The diagnosis of CF: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr 132 (1998) 589-595
18. Farrell P.M., Lai H.J., Kosorok M.R., Laxova A., Green C.G., Collins J., et al. Evidence of improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: enough is enough. J Pediatr 147 3 Suppl (2005) S30-S36
19. Centers for Disease Control and Prevention. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for newborn screening programs. Proceedings of a 2003 workshop. MMWR Morb Mortal Wkly Rep 53 (2004) 1-36
20. Southern K.W., Munck A., Pollitt R., Travert G., Zanolla L., Dankert-Roelse J., et al. A survey of newborn screening for cystic fibrosis in Europe. J Cyst Fibros 6 (2007) 57-65
21. Cheillan D., Vercherat M., Chevalier-Porst F., Charcosset M., Rolland M.O., and Dorche C. False-positive results in neonatal screening for cystic fibrosis based on a three-stage protocol (IRT/DNA/IRT): should we adjust IRT cutoff to ethnic origin?. J Inherit Metab Dis 28 (2005) 813-818
22. Lecoq I., Brouard J., Laroche D., Ferec C., and Travert G. Blood immunoreactive trypsinogen concentrations are genetically determined in healthy and CF newborns. Acta Paediatr 88 (1999) 338-341
23. Wilfond B.S., and Gollust S.E. Policy issues for expanding newborn screening programs: the cystic fibrosis newborn screening experience in the United States. J Pediatr 146 (2005) 668-674
24. Comeau A.M., Parad R.B., Dorkin H.L., Dovey M., Gerstte R., Haver K., et al. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. Pediatrics 113 (2004) 1811-1812
25. Ciske D.J., Haavisto A., Laxova A., Rock L.Z., and Farrell P.M. Genetic counselling and neonatal screening for cystic fibrosis: an assessment of the communication process. Pediatrics 07 (2001) 699-705
26. Sarles J., Berthezene P., Le Louarn C., Somma C., Perini J.M., Catheline M., et al. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis. J Pediatr 147 (2005) 302-305
27. Rock M.J., Hoffman G., Laessing R.H., Kopish G.J., Litsheim T.J., and Farrell P.M. Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing. J Pediatr 147 (2005) S73-S77
28. Massie R.J., Olsen M., Glazner J., Robertson C.F., and Francis I. NBS for CF in Victoria: 10 year's experience. Med J Austr 172 (2000) 584-587
29. Padoan R., Bassotti A., Seia M., and Corbetta C. Negative sweat test in hypertrypsinaemic infants with cystic fibrosis carrying rare CFRT mutations. Eur J Pediatr 161 (2002) 212-215
30. Kiesewetter S., and Macek M. A mutation in CFTR produces different phenotypes depending on chromosomal background. Mat Genet 5 (1993) 274-278
31. Castellani C., Tamanini A., and Mastella G. Protracted neonatal hypertrypsinaemia, normal sweat chloride and cystic fibrosis. Arch Dis Child 82 (2000) 481-482
32. O'Sullivan B.P., Zwerdling R.G., Dorkin H.L., Comeau A.M., and Parad R. Early pulmonary manifestation of cystic fibrosis in children with the Delta F 508/R117H-7T genotype. Pediatrics 118 (2006) 1260-1265
33. Roussey M., Le Bihannic A., Scotet V., Audrezet M.P., Blayau M., Dagorne, et al. Neonatal screening of cystic fibrosis: diagnostic problems with CFTR mild mutations. J Inherit Metab Dis 30 (2007) 613 Epub Jul 12 2007
34. Scotet V., Audrezet M.P., Roussey M., Rault G., Dirou-Prigent A., Journel H., et al. Immunoreactive trypsin/DNA newborn screening for cystic fibrosis: should the R117H variant be included in CFTR mutation panels?. Pediatrics 118 (2006) e1523-e1529